Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03858751
PHASE1/PHASE2

Pharmacological Activation of HMN for OSA Aim 2

Sponsor: Brigham and Women's Hospital

View on ClinicalTrials.gov

Summary

Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal subjects. In this protocol the investigators will test the effect of LTM1201AZ, LTM1201AT, LTM1201AD, LTM1201AG administered before sleep on OSA phenotype traits and OSA severity during sleep.

Official title: Pharmacological Activation of Hypoglossal Motor Nucleus for Obstructive Sleep Apnea Aim 2

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

16

Start Date

2019-03-01

Completion Date

2022-12-31

Last Updated

2022-09-21

Healthy Volunteers

No

Interventions

DRUG

Placebo oral capsule

Placebo capsule before bedtime

DRUG

LTM1201AZ

LTM1201AZ oral capsule before sleep

DRUG

LTM1201AT

LTM1201AT oral capsule before sleep

DRUG

LTM1201AG

LTM1201AG oral capsule before sleep

DRUG

LTM1201AD

LTM1201AD oral capsule before sleep

Locations (1)

Brigham and Women's Hospital

Boston, Massachusetts, United States